II. Mechanism
III. Indications
- Atrial Fibrillation Anticoagulation
-
Deep Vein Thrombosis
- However, must be started concurrently with Heparin, unlike other Factor Xa Inhibitors (Apixaban, Rivaroxaban)
IV. Contraindications
- Creatinine Clearance <15 ml/min/1.73m2
- Creatinine Clearance >95 ml/min/1.73m2 (lower efficacy due to high drug clearance)
- Severe Cirrhosis (Child-Pugh Class C)
V. Dosing
- Standard dose: 60 mg orally daily
- Half dose indications (30 mg orally daily)
- Creatinine Clearance 15 to 50 ml/min/1.73m2 OR
- Weight <60 kg
VI. Pharmacokinetics
- Oral Bioavailability: 62%
- Half-Life: 10-14 hours
- Onset: 1-2 hours
- Renal Clearance 50%
VII. Drug Interactions
VIII. Safety
- Unknown Safety in Pregnancy
- Unknown Safety in Lactation
IX. Resources
Images: Related links to external sites (from Bing)
Related Studies
savaysa (on 7/20/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
SAVAYSA 60 MG TABLET | $12.46 each |
Ontology: edoxaban (C2975435)
Definition (NCI) | An orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Edoxaban is administered as edoxaban tosylate. This agent has an elimination half-life of 9-11 hours and undergoes renal excretion. |
Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
MSH | C552171 |
English | edoxaban, Edoxaban, Ethanediamide, n1-(5-chloro-2-pyridinyl)-n2-((1s,2r,4s)-4- ((dimethylamino)carbonyl)- 2-(((4,5,6,7-tetrahydro-5-methylthiazolo(5,4-c)pyridin-2-yl)carbonyl)amino)cyclohexyl)-, N-(5-chloropyridin-2-yl)-N'-((1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)ethanediamide p-toluenesulfonate monohydrate, N-(5-chloropyridin-2-yl)-N'-[(1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl]oxamide, EDOXABAN |